Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220862378> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W4220862378 endingPage "e7" @default.
- W4220862378 startingPage "e7" @default.
- W4220862378 abstract "<h3>Purpose/Objective(s)</h3> PD-1 inhibition (PD1i) has demonstrated no benefit for locally advanced HNSCC, and emerging neoadjuvant PD1i window of opportunity yield promising but limited responses. Our preclinical work demonstrates that ablating tumor draining lymphatics compromises the response to immune-oncology (IO) therapy. In concert, a recently completed phase I trial investigating neoadjuvant immunoradiotherapy (NIRT) – 8Gy to gross tumor volume plus PD1i followed by surgery – for treatment-naïve HPV- HNSCC demonstrated a 60% major pathologic (>25%) response and clinical to pathologic downstaging of 100% (NCT03247712). Accordingly, we hypothesize that lymphatic-preserving immune oncology (IO) therapy can potentiate PD1i and promote antitumor immunity by enhancing immunosurveillance along the tumor-immune-lymphatic axis and reversing the suppressive tumor immune microenvironment (TIME). <h3>Materials/Methods</h3> To explore this, we employed our recently characterized tobacco-signature, orthotopic murine oral squamous cell carcinoma (OSCC) models, one of which matches the immune infiltrate and PD1i response of human OSCC and the other of which is immune-cold with no response to PD1i. Using these models, we delivered sequences of NIRT along with procedures to ablate tumor-draining lymph nodes (tdLNs) or lymphatic channels to characterize the immune mechanisms that optimize antitumor immunity and therapy response. <h3>Results</h3> We define a NIRT scheme that spares tumor lymphatics and leads to complete and durable immunity in our immune-responsive OSCC preclinical model. By ablating tumor-draining lymphatics, we find that tdLNs are critical for the NIRT response. Moreover, we interrupt draining lymphatics to the sentinel lymph node (SLN), mapped with an IRDye-tagged tilmanocept, to explore immunosurveillance across the tumor-immune-lymphatic axis. Lymphatic channel ablation blocks the tumor NIRT response and leads to a restriction of cytotoxic, tumor-antigen specific CD8 T cells from the TIME. Within tdLNs, we find that conventional type I dendritic cells are necessary for the NIRT response and enhanced following NIRT. Lastly, we find that NIRT reverses local immunosuppression by reducing myeloid derived suppressor cells within the TIME, potentiating PD1i and leading to complete response in our immune-cold model. <h3>Conclusion</h3> We demonstrate that targeting tumors with stereotactic radiation and PD1i while sparing draining lymphatics enhances anticancer immunity by promoting regional immunosurveillance and repolarizing local suppressive TIMEs, resulting in significantly improved responses. Overall, this work represents a paradigm-shift in the design of IO therapies, which can immediately inform the design of next-generation immune oncology trials for HNSCC." @default.
- W4220862378 created "2022-04-03" @default.
- W4220862378 creator A5017600358 @default.
- W4220862378 creator A5017908070 @default.
- W4220862378 creator A5035916034 @default.
- W4220862378 creator A5051978127 @default.
- W4220862378 creator A5058684304 @default.
- W4220862378 creator A5067524245 @default.
- W4220862378 creator A5071345192 @default.
- W4220862378 creator A5080812312 @default.
- W4220862378 date "2022-04-01" @default.
- W4220862378 modified "2023-10-16" @default.
- W4220862378 title "Neoadjuvant Immunoradiotherapy in a Tobacco-Signature Preclinical Oral Squamous Cell Carcinoma Model" @default.
- W4220862378 doi "https://doi.org/10.1016/j.ijrobp.2021.12.021" @default.
- W4220862378 hasPublicationYear "2022" @default.
- W4220862378 type Work @default.
- W4220862378 citedByCount "0" @default.
- W4220862378 crossrefType "journal-article" @default.
- W4220862378 hasAuthorship W4220862378A5017600358 @default.
- W4220862378 hasAuthorship W4220862378A5017908070 @default.
- W4220862378 hasAuthorship W4220862378A5035916034 @default.
- W4220862378 hasAuthorship W4220862378A5051978127 @default.
- W4220862378 hasAuthorship W4220862378A5058684304 @default.
- W4220862378 hasAuthorship W4220862378A5067524245 @default.
- W4220862378 hasAuthorship W4220862378A5071345192 @default.
- W4220862378 hasAuthorship W4220862378A5080812312 @default.
- W4220862378 hasConcept C121608353 @default.
- W4220862378 hasConcept C126322002 @default.
- W4220862378 hasConcept C143998085 @default.
- W4220862378 hasConcept C181152851 @default.
- W4220862378 hasConcept C203014093 @default.
- W4220862378 hasConcept C2776107976 @default.
- W4220862378 hasConcept C2776636583 @default.
- W4220862378 hasConcept C2776885095 @default.
- W4220862378 hasConcept C2777701055 @default.
- W4220862378 hasConcept C2778292576 @default.
- W4220862378 hasConcept C2778326572 @default.
- W4220862378 hasConcept C2779013556 @default.
- W4220862378 hasConcept C2780212769 @default.
- W4220862378 hasConcept C2780849966 @default.
- W4220862378 hasConcept C502942594 @default.
- W4220862378 hasConcept C530470458 @default.
- W4220862378 hasConcept C71924100 @default.
- W4220862378 hasConcept C8891405 @default.
- W4220862378 hasConceptScore W4220862378C121608353 @default.
- W4220862378 hasConceptScore W4220862378C126322002 @default.
- W4220862378 hasConceptScore W4220862378C143998085 @default.
- W4220862378 hasConceptScore W4220862378C181152851 @default.
- W4220862378 hasConceptScore W4220862378C203014093 @default.
- W4220862378 hasConceptScore W4220862378C2776107976 @default.
- W4220862378 hasConceptScore W4220862378C2776636583 @default.
- W4220862378 hasConceptScore W4220862378C2776885095 @default.
- W4220862378 hasConceptScore W4220862378C2777701055 @default.
- W4220862378 hasConceptScore W4220862378C2778292576 @default.
- W4220862378 hasConceptScore W4220862378C2778326572 @default.
- W4220862378 hasConceptScore W4220862378C2779013556 @default.
- W4220862378 hasConceptScore W4220862378C2780212769 @default.
- W4220862378 hasConceptScore W4220862378C2780849966 @default.
- W4220862378 hasConceptScore W4220862378C502942594 @default.
- W4220862378 hasConceptScore W4220862378C530470458 @default.
- W4220862378 hasConceptScore W4220862378C71924100 @default.
- W4220862378 hasConceptScore W4220862378C8891405 @default.
- W4220862378 hasIssue "5" @default.
- W4220862378 hasLocation W42208623781 @default.
- W4220862378 hasOpenAccess W4220862378 @default.
- W4220862378 hasPrimaryLocation W42208623781 @default.
- W4220862378 hasRelatedWork W1999524151 @default.
- W4220862378 hasRelatedWork W2033779312 @default.
- W4220862378 hasRelatedWork W2511835027 @default.
- W4220862378 hasRelatedWork W2593287400 @default.
- W4220862378 hasRelatedWork W2736841625 @default.
- W4220862378 hasRelatedWork W2766512176 @default.
- W4220862378 hasRelatedWork W2938706471 @default.
- W4220862378 hasRelatedWork W3144494241 @default.
- W4220862378 hasRelatedWork W4220862378 @default.
- W4220862378 hasRelatedWork W4291378227 @default.
- W4220862378 hasVolume "112" @default.
- W4220862378 isParatext "false" @default.
- W4220862378 isRetracted "false" @default.
- W4220862378 workType "article" @default.